STP-100 A preclinical antibody-drug conjugate candidate targeting a tumor-specific cell-surface epitope, with clinical studies planned for early 2027.
Visit productCosigns Received
Be the first Cosign
Put your name behind STP-100.
Add it to your Products I use list and share why you use it.